CEA mRNA identification in peripheral blood is feasible for colorectal, but not for gastric or pancreatic cancer staging

Piva, Maria Grazia; Fogar, Paola; Navaglia, Filippo; Basso, Daniela; Roveroni, Giovanni; Gallo, N.; Zambon, Carlo-Federico; Pedrazzoli, Sergio; Plebani, Mario

doi:10.1016/s1590-8658(00)80682-9

Cited by 8 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[13][14][15] However, the specificity and sensitivity of these markers are important. Bustin et al 16 reported the expression of CK19 and CK20 mRNA in 30% and 100%, respectively, of the samples taken form healthy volunteers.…”

Section: Discussionmentioning

confidence: 99%

Detection of Circulating Cancer Cells After a Gastrectomy for Gastric Cancer

Ikeguchi

Kaibara

2005

Surg Today

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Detection of Circulating Cancer Cells After a Gastrectomy for Gastric Cancer

Ikeguchi

Kaibara

2005

Surg Today

View full text Add to dashboard Cite

show abstract

“…Then 39 studies were excluded because of redundancy or the lack of an outcome of interest. The remaining 26 studies, comprised of seven studies for BM, 9,[15][16][17][18][19][20] 18 studies for PB, 8,[21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37] one study for BM/PB 38 and no studies for MPB, met the selection criteria for the final analysis ( Fig. 1).…”

Section: Baseline Characteristics Of Included Studiesmentioning

confidence: 99%

Clinicopathological and prognostic significance of circulating tumor cells in patients with gastric cancer: A meta-analysis

et al. 2014

View full text Add to dashboard Cite

The prognostic significance of circulating tumor cells (CTCs) and disseminated tumor cells (DTCs) in patients with gastric cancer (GC) is controversial. The aims of our meta-analysis are to assess its correlation with clinicopathological characteristics and prognostic significance in GC. PubMed, Embase, the Cochrane database, the Science citation index, the CNKI database and the references of relevant studies were systematically searched (up to November, 2013). Using the random-effect model, the meta-analysis was completed with odds ratio (OR), risk ratio, hazard ratio (HR) and 95% confidence intervals (CI) as effect values. Twenty-six studies containing 2,566 patients with GC were analyzed. The overall analysis showed that the incidence difference of tumor cells (CTCs/DTCs) was significant when comparing the stage I/II group to the stage III/IV group (OR 5 0.36, CI [0.23, 0.56 Gastric cancer (GC) is the fourth most frequently diagnosed cancer and second leading cause of cancer death worldwide.1 Curative resection remains common and the main treatment for GC. Even though the clinical prognosis for GC has been improved by the development of surgery and adjuvant chemoradiotherapy, 2 the long-term survival of advanced GC patients is highly unsatisfactory and hindered by recurrence and distant metastasis.In recent years, extensive studies have demonstrated that tumor cells in bone marrow (BM, i.e., disseminated tumor cells [DTCs]) and peripheral blood (PB, i.e., circulating tumor cells [CTCs]), 3 which were first reported by Ashworth in 1869, 4 are related to tumor metastasis and relapse. Currently, highly sensitive and specific diagnostic methods have been developed and used for tumor cell detection, including reverse-transcriptase polymerase chain reaction (RT-PCR), immunocytochemistry (ICC), flow cytometry (FCM), and the CellSearch system that targets either tumor-associated mRNA or cytokeratin (CK) isozymes. 5 Many researchers using these

show abstract

“…Molecular analyses have been performed in only a small number of cases [2,50,57,66,67]. Neither detection in the bone marrow nor detection in the blood has been evaluated for prognostic impact.…”

Section: Pancreatic Carcinomamentioning

confidence: 99%

Disseminated tumour cells

Vogel

Kalthoff

2001

Virchows Arch

View full text Add to dashboard Cite

Metastatic spread is a major factor in the prognosis of cancer patients. Early detection and eradication of circulating tumour cells prior to the development of metastases could help to improve the outcome of patients after tumour resection. Disseminated tumour cells have been detected in different compartments of the body using cytological and immunostaining methods and, more recently, using different molecular biological techniques. The most frequently studied body compartments are the bone marrow, peritoneal cavity, blood and lymph nodes, but other body fluids such as urine, bile, pancreatic juice and sputum have also been analysed. At all of these sites, tumour cells have been detected. However, the specificity and sensitivity of the methods and their prognostic impact are still being debated. This review discusses the accuracy of the detection methods and the prognostic value of detecting disseminated tumour cells in the bone marrow, blood and peritoneal lavage of patients with colorectal, gastric and pancreatic carcinomas.

show abstract

CEA mRNA identification in peripheral blood is feasible for colorectal, but not for gastric or pancreatic cancer staging

Cited by 8 publications

References 0 publications

Detection of Circulating Cancer Cells After a Gastrectomy for Gastric Cancer

Detection of Circulating Cancer Cells After a Gastrectomy for Gastric Cancer

Clinicopathological and prognostic significance of circulating tumor cells in patients with gastric cancer: A meta-analysis

Disseminated tumour cells

Contact Info

Product

Resources

About